Literature DB >> 12955638

Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection.

Scott A Bernhardt1, Theodore Spilker, Todd Coffey, John J LiPuma.   

Abstract

Persons with cystic fibrosis (CF) are susceptible to chronic pulmonary infection due to certain Burkholderia species, but it is not clear whether this typically involves persistent infection with the same strain or sequential infection with distinct strains. We analyzed 1095 Burkholderia isolates recovered from serial sputum cultures from 379 patients with CF receiving care in 112 CF treatment centers in the United States. Genotyping was performed by random amplified polymorphic DNA typing or pulsed-field gel electrophoresis. Overall, a change in infecting strain was found in 24 (6.9%) of 347 patients infected with Burkholderia cepacia complex and in 3 (9%) of 32 patients infected with Burkholderia gladioli. Several patients were likely coinfected, at least transiently, with >1 B. cepacia complex strain. The potential for strain replacement during chronic infection may confound studies of the relationship between strain and clinical outcome and must be considered in designing effective infection-control practices.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955638     DOI: 10.1086/377541

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Direct culture-independent Strain typing of Burkholderia cepacia complex in sputum samples from patients with cystic fibrosis.

Authors:  Pavel Drevinek; Sarka Vosahlikova; Klara Dedeckova; Ondrej Cinek; Eshwar Mahenthiralingam
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

2.  Burkholderia cenocepacia J2315 escapes to the cytosol and actively subverts autophagy in human macrophages.

Authors:  Souhaila Al-Khodor; Kimberly Marshall-Batty; Vinod Nair; Li Ding; David E Greenberg; Iain D C Fraser
Journal:  Cell Microbiol       Date:  2013-11-06       Impact factor: 3.715

3.  Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia-complex isolates from an Italian cystic fibrosis centre.

Authors:  G Golini; G Cazzola; R Fontana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

4.  Burkholderia cepacia complex in cystic fibrosis in the post-epidemic period: multilocus sequence typing-based approach.

Authors:  Libor Fila; Pavel Dřevínek
Journal:  Folia Microbiol (Praha)       Date:  2017-03-31       Impact factor: 2.099

Review 5.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Burkholderia cepacia complex in Serbian patients with cystic fibrosis: prevalence and molecular epidemiology.

Authors:  Z V Vasiljevic; K Novovic; M Kojic; P Minic; A Sovtic; S Djukic; B Jovcic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-13       Impact factor: 3.267

7.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 8.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

Review 9.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center.

Authors:  David E Greenberg; Joanna B Goldberg; Frida Stock; Patrick R Murray; Steven M Holland; John J Lipuma
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.